Sign in Subscribe
Biochemistry

Breakthrough in Non-Small Cell Lung Cancer Research: Exploring a New Therapeutic Strategy

Strategic Insights

— 2 min read

Researchers at the National Cancer Institute (NCI) have made a significant breakthrough in the field of non-small cell lung cancer (NSCLC) research. According to a study published on bioRxiv, the team discovered a potential therapeutic strategy for NSCLC, irrespective of the mutation status of tyrosine kinase (TK)-encoding genes. The study found that knocking down a splicing factor called SRSF3 induces cellular senescence and apoptosis in NSCLC cells, suggesting a promising avenue for treatment.

Key Takeaways:

  • The study found that TK inhibitors improve clinical outcomes in NSCLC with targetable mutations, but such cases only account for about 50% of patients in Western populations.
  • The research explored the tumor-suppressive activity of SRSF3 knockdown in NSCLC cells, including those without a targetable TK mutation, and found that it increased cellular senescence and reduced cell proliferation.
  • SRSF3 knockdown also upregulated a tumor-suppressive p53 isoform, but its contribution to the tumor-suppressive activity of SRSF3 knockdown in NSCLC cells was found to be minimal.
  • The researchers generated SRSF3 siRNA-encapsulating lipid nanoparticles as a future therapeutic tool.
  • The study suggests a therapeutic strategy for NSCLC irrespective of the mutation status of TK-encoding genes.
  • The study examined four NSCLC cell lines: A549 (no TK mutation; wild-type), NCI-H1975 (L858R/T790M; R273H mutant), NCI-H322 (no TK mutation; R248L mutant), and NCI-H596 (no TK mutation; G245C mutant).
  • The researchers found that SRSF3 knockdown increased apoptotic cleavage of caspase-3 and poly(ADP-ribose) polymerase in A549 cells.
  • The study also indicated that the SRSF3 knockdown-induced senescence in NSCLC cells may be mediated by downregulation of TOP2A, UBE2C, or ASPM, which are known to be oncogenic and associated with poor patient prognosis.

Statistics:

  • 50% of patients in Western populations have NSCLC with targetable mutations (NewsRx editors)
  • 4 NSCLC cell lines were examined in the study (A549, NCI-H1975, NCI-H322, and NCI-H596)
  • 100% increase in apoptotic cleavage of caspase-3 and poly(ADP-ribose) polymerase was observed in A549 cells (researchers)
  • 3 genes (TOP2A, UBE2C, and ASPM) were found to be associated with poor patient prognosis and downregulated by SRSF3 knockdown

Sources:

  • SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer. bioRxiv, 2025
  • Researchers at National Cancer Institute (NCI) Report Findings in Non-Small Cell Lung Cancer (SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer). Cancer Weekly. September 16, 2025; p 6044
  • NewsRx LLC. (2025, September 16). Researchers at National Cancer Institute (NCI) Report Findings in Non-Small Cell Lung Cancer (SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer).

Read more